Nykredit A/S’s Celldex Therapeutics CLDX Stock Holding History
Bought
Maintained
Sold
Other funds holding CLDX
KCM
BBA
Nykredit A/S's CLDX Position: Q3 2026 in Review
Nykredit A/S held its Celldex Therapeutics (CLDX) position steady in Q3 2026 at 1,793 shares worth $58.1K. The position accounts for ﹤0.01% of the portfolio, ranked #1469.
Nykredit A/S first reported a position in CLDX in Q2 2026 and has held it in 2 quarters since. The position peaked at $66.7K in Q2 2026. 249 funds tracked by Wall St. Rank hold CLDX as of Q3 2026.
- Nykredit A/S held 1,793 shares of Celldex Therapeutics worth $58.1K as of Q3 2026.
- Nykredit A/S left its Celldex Therapeutics share count unchanged in Q3 2026.
- Celldex Therapeutics made up ﹤0.01% of Nykredit A/S's portfolio in Q3 2026, its #1469 holding.
- Nykredit A/S first reported a position in Celldex Therapeutics in Q2 2026 and has held it in 2 quarters since.
- Nykredit A/S's Celldex Therapeutics position peaked at $66.7K in Q2 2026.
- 249 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q3 2026.
Based on Nykredit A/S's 13F filing for Q3 2026, filed 6 Nov 2026.